Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cryoport, Inc. on September 10, 2010. The filing discloses the appointment of a new senior executive officer to the Company's leadership team.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation and stock option pricing.
Material Changes
The primary material change reported is the appointment of Michael Bartholomew as Chief Commercialization Officer effective September 10, 2010. Mr. Bartholomew brings 20 years of experience in marketing and sales management within the pharmaceuticals and materials industries, including prior roles at DDN Pharmaceutical Logistics, Alby Materials, and Pfizer, Inc.
Compensation and Equity Grants
- Base Salary: $18,750 per month.
- Incentive Bonus: Targeted at 30% of annual base salary.
- Stock Option Grant 1: 150,000 shares at an exercise price of $0.78 per share. Vesting begins six months after continuous employment and continues in equal six-month installments over four years.
- Stock Option Grant 2: 100,000 shares at an exercise price of $0.78 per share. This grant fully vests upon the Company achieving six months of sustainable positive cash flow.
Outlook and Risks
The filing does not contain specific guidance, outlook, or risk factors beyond the standard disclosure of the executive appointment. The vesting condition for the second stock option grant implies a strategic focus on achieving sustainable positive cash flow.
Key Facts for Investor Verification
- Verify the Company's current cash flow status to assess the likelihood of the performance-based stock option vesting.
- Confirm the total number of shares authorized for issuance under the Company's equity incentive plans to evaluate potential dilution from the 250,000 new options granted.
- Review the Company's recent financial reports to understand the context of the new commercial leadership appointment relative to current sales performance.